Therefore, current expert consensus emphasizes that mitigation strategies—such as pausing therapy during acute illness or perioperative periods, maintaining adequate caloric and carbohydrate intake, and educating patients about early symptom recognition—are equally applicable regardless of which SGLT2 inhibitor is prescribed in HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.